Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.

ABSTRACT:

Purpose

We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy.

Methods

Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10-12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression.

Results

We accrued 106 patients, of whom 61 completed the serial (18)F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respective

SUBMITTER: Choi NC 

PROVIDER: S-EPMC3644202 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature